Medical beauty is mainly divided into four types: plastic surgery, skin beauty, injection beauty and oral beauty. Non-surgical micro-plastic surgery projects with high frequency and low price, non-invasive and anti-aging are the future development trend. The medical and beauty industry chain mainly includes three parts: upstream medical product manufacturers, mid-stream medical institutions and end consumers. First, the industry is in a high-speed growth period China's medical beauty industry is in a high-speed growth period, and the industry expects a compound growth rate of 32% in the next five years. In 2015, the official statistics of plastic surgery were 7 million person-times, and the average annual growth rate was 13.40%. It is estimated that it will exceed 11.1 million in 2018. Judging from the number of per capita medical treatments, in 2015, China was only less than 3 person/thousand people, far lower than South Korea's 19 person/thousand people and Taiwan's 9-10 person/thousand people. The subsequent growth potential is huge. The Chinese medical and beauty consumer groups tend to be younger and broader. The proportion of medical consumers under the age of 25 rose from 1% in 2009 to 14% in 2015, and it has an earlier trend in injection beauty and facial equipment. With the change of consumer attitudes and the improvement of spending power, more and more women over the age of 40 have gradually chosen medical beauty to improve their quality of life. At present, in domestic medical aesthetic surgery, males account for 6-8%, lower than the global average of 12%, and the future will also be a potential power point. Second, standardized development is the future direction At present, the advertising-type private institutions in the domestic medical industry are in the mainstream, and the income cost is double-high. Excessive advertising costs are the pain point of domestic medical institutions, and up to 91% of advertising costs are directed to search engines. The future is worth learning from the Hong Kong model, giving full play to the combination of big data and the Internet. We believe that funds, doctors and licenses are the three thresholds of the industry. General medical institutions need a training period of 3-5 years, during which time the amount of funds required is huge. Private small and medium-sized medical institutions with a proportion of more than 70% have only about 35% of the doctor's resources and market share in the country, and there is a huge gap in doctor resources. The lack of uniformity in the distribution of licenses is also a challenge in the expansion process. We judge that polarization and standardization are the future of China's medical and aesthetic industry. Large-scale chain institutions pay attention to brand effect, quality and safety guarantee, mature incentive mechanism and large platform to attract well-known physicians, scale efficiency to reduce marketing and operating costs, rapid replication to gain market share; personal clinics, outpatient departments, etc., through price advantage, mouth According to legend, word of mouth to get a living space. The medical and aesthetic industry will introduce detailed regulatory standards, standardization and standardization to help the industry develop healthily. Third, investment advice and investment targets China's medical and beauty industry is in a period of rapid growth, and the continued involvement of large amounts of capital and the increasingly standardized regulation of the industry itself will further promote changes in industrial growth and competition. As a fast-growing emerging industry, there are not many A-share listed companies, so they have the scarcity attributes of investment. The recommendations for specific targets are as follows: 1. Focus on Langzi shares (002612) (002612, BUY). The company's high starting point layout makes it the first real medical standard for the motherboard, and it is expected to obtain a certain premium in valuation. 2. Appropriate attention to the new three boards of Huahan Plastic (430335, unrated), Limecon (832533, unrated) and Lido Plastic (834480, unrated), the main business focuses on medical beauty, although the current scale is not large, but The use of the capital market is undergoing a nationwide expansion, and subsequent development needs to continue to follow. Risk warning: industry medical disputes, new product development risks, industry regulatory policy risks, company industry integration and war Slightly adjusted challenges and so on. Fourth, individual stock analysis Langzi shares Integrate excellent medical and beauty resources at home and abroad On June 20, the company announced that it plans to raise 900 million yuan of non-public offering funds, mainly to: 1, medical beauty service projects; 2, Akabang brand marketing network construction projects. The medical beauty service project construction period is 2 years. Based on the current Chinese and Korean medical and beauty resources for the current investment, the company plans to adopt a business expansion strategy of “regional brand precipitation†and “national chain operation†to precipitate in the women’s business cluster. The key cities will build a three-dimensional medical beauty service network that meets the multi-level consumer multi-level needs: A. The company plans to open three comprehensive medical treatments with a business area of ​​8,000-10,000 square meters and high-end elegance in the first-tier cities in the next two years. The hospital provides comprehensive medical and beauty services such as cosmetic surgery, cosmetic dermatology, and cosmetic dentistry; B. The company plans to open 30 medical beauty clinics with a business area of ​​about 1,000 square meters in the first-tier cities and other economically developed cities in the next two years. The outpatient department radiates to the periphery centering on a comprehensive medical beauty hospital, focusing on medical rejuvenation services such as laser beauty, injection beauty, and anti-aging. Suning Global Joining Korea ID Group to enter the medical and beauty industry On January 14, 2016, the company announced plans to establish a joint venture company with the ID Health Industry Group of Korea in China, with a registered capital of not less than 600 million yuan. The cooperation between Suning and ID Group has achieved a substantial breakthrough in the transformation of the company's big health industry. Korea ID Health Industry Group is Korea's largest health care group. Its industrial layout includes ID medical beauty, hospital channel cosmetics, stem cells, health testing, training, etc. It has world-class industrial technology capabilities, Korea's top professional talent team, and efficient Global customer guidance and medical marketing capabilities. The capital increase and the establishment of a joint venture company, the introduction of first-class international resources into China will fully increase the company's competitiveness in the field of medical beauty. *ST alloy 2 billion increase for the reconstruction and expansion of Sichuan Huapu Hospital On November 20, 2015, the company announced that the total amount of funds raised from non-public issuance will not exceed RMB 2 billion. After deducting the issuance expenses, it is planned to be used for the construction and operation of the reconstruction and expansion of PPP projects in Sichuan Huapu Hospital. The main construction content is 1 international. Plastic surgery hospital, 1 maternity hospital, 1 international hospital, 1 general hospital, 1 medical center (1-4 floors for business), underground parking lot, outdoor general plan project, etc. Among them, the International Plastic Surgery Hospital has five floors above ground and a total building height of 23.70m. It mainly conducts self-operated business with a total construction area of ​​11,488m2. Actively participating in the medical and health industry also reflects the company's optimism and confidence in its prospects. 21" Sanitary Sleeve For Embryo Transfer 21 Inches Sanitary Sleeve,Disposable Sanitary Chemise,Embryo Transfer Cover,Et Sheath Cover Jinan Mucho Commercial Inc. , https://www.muchovet.com